OncologyEducation is proud to host the 2018 CAMO Evening Symposium focused on biosimilars and their integration into clinical practice.
This live educational program will be Co-Chaired by Dr. Scott Berry and Dr. Sunil Verma.


Learning Objectives:

  1. Review fundamental biology of biosimilars.
  2. Discuss policy issues governing the approval and clinical use of biosimilars.
  3. Describe the current availability of biosimilars and their integration into clinical practice.
  4. Investigate the challenges regarding biosimilars, their integration into clinical practice and patient treatment.

Target Audience: 

Medical oncologists, pharmacists, nurses, students, fellows, residents, general practitioners in oncology. 


Program Details: 

Agenda:
5:30 p.m.- 6:00 p.m.
Registration

6:00 p.m. - 6:10 p.m.
Welcome Introduction from Chairs
Dr. Scott Berry
Dr. Sunil Verma

6:10 p.m. - 6:30 p.m.
Understanding the science of Biosimilars:
How are they different from emerging drugs? What are they and how are they created?
Dr. Sandy Sehdev

6:30 p.m. - 6:45 p.m
From Bench to Bedside: Getting Biosimilars into the Clinic
Dr. Scott Berry

6:45 p.m. - 7:00 p.m.
Clinical Opportunities and Challenges in Incorporation of Biosimilars in Breast Cancer
Dr. Sunil Verma

7:00 p.m. - 7:30 p.m.
Dinner Break

7:30 p.m.-7:45 p.m.
Update from CADTH on Biosimilars
Alexandra Chambers 

7:45 p.m. - 8:30 p.m.
Panel Discussion
Featuring:

Dr. Scott Berry
Dr. Sunil Verma
Dr. Hal Hirte,  President, CAMO
Dr. Sandy Sehdev
Dr. Andrea Eisen, Cancer Care Ontario Perspective
Flay Charbonneau,  Pharmacy Perspective
Barry Stein, Patient Advocacy Perspective
Alexandra Chambers, CADTH Perspective

8:30 p.m. - 8:45 p.m.
Closing Remarks from Chairs

Dr. Scott Berry
Dr. Sunil Verma
Dr. Hal Hirte, President, CAMO


Venue:

Wednesday, April 25th, 2018
Chelsea Hotel
33 Gerrard St W
Toronto, ON M5G 1Z4


 

About the Chairs: 

Dr. Scott Berry, BSc, MD, MHSc, FRCPC

Dr. Berry is a medical oncologist at Sunnybrook Odette Cancer Centre and an Associate Professor in the Faculty of Medicine at the University of Toronto. He completed his general medical training and medical oncology training at the University of Toronto. Dr. Berry is an active participant in clinical research at the National Cancer Institute of Canada (NCIC) Clinical Trials Group and the North American Intergroup. He has been involved in important international trials in colorectal cancer that have been published in journals including the New England Journal of Medicine and the Annals of Oncology. Dr. Berry has also authored several prostate and colorectal cancer guidelines for the Cancer Care Ontario Program in Evidence Based Care and chaired national consensus guideline meetings for the Colorectal Cancer Association of Canada.

Dr. Berry also loves teaching and holds several leadership positions in education. He has won several teaching awards including the University of Toronto Division of Medical Oncology Education Award. He chairs the Royal College of Physicians and Surgeons of Canada Specialty Committee for Medical Oncology. He is the Program Director for the Medical Oncology Training Program at the University of Toronto and Co-Medical Director of www.OncologyEducation.com.

His other academic interests are the bioethical issues surrounding the care of people with cancer, in particular the ethical issues surrounding funding new and expensive cancer medications. Dr. Berry holds a master's degree in bioethics from the University of Toronto. He has also served on the ASCO Ethics Committee and is the ethics advisor to the pan-Canadian Oncology Drug Review and the NCIC Data Safety Monitoring Committee. 

Dr. Sunil Verma, MD, MSEd, FRCPC

Dr. Verma is a Professor at the University of Calgary and Medical Director at the Tom Baker Cancer Centre. He completed his internal medicine and medical oncology training at the University of Alberta and then went on to a fellowship in breast cancer at the University of Toronto. He also completed his Master of Science in medical education from the University of California during his fellowship years.

Dr. Verma’s main clinical interests are in the treatment and management of breast cancer and lung cancer. He also has key research interests in neoadjuvant and endocrine treatment of breast cancer, reducing toxicity of systemic treatment, and developing novel therapies in breast and lung cancer. He has won numerous teaching awards and has also been recognized with many awards for his mentorship.



Dr. Verma has led and created a number of national and international educational projects in oncology. He is well published, including being first author in New England Journal of Medicine along with other prestigious journals and is recognized internationally for his research and education leadership in breast and lung cancer. He is a member of several professional societies including ASCO, the Canadian Association of Medical Oncologists, and the Canadian Medical Association.


Other Information

For more information, please send requests to  andrea@oncologyeducation.com.
 


Program Sponsors

 

   
 

 

 

Oncology Clinical News

Surgery May Benefit Some With Early Prostate Cancer: Study

(U.S. News & World Report/HealthDay News) Dec 12, 2018 - For certain men with early prostate cancer, choosing surgery over "watchful waiting" may add a few years to their lives, a new study suggests. European researchers found that among nearly 700 men with earlier-stage prostate cancer, those who received surgery to remove the gland lived three years longer, on average, than those assigned to watchful waiting. However, experts had major caveats about the study, which followed men who were treated for prostate cancer 20 to 30 years ago.
Read full article.

Fetal Tissue Research Targeted by Abortion Foes Inside Administration


Read full article.

Excess Body Weight Responsible For 4% Of Cancers Worldwide, Study Says

(CNN) Dec 12, 2018 - Excess body weight was responsible for 3.9% of cancer globally, or 544,300 cases, in 2012, according to a new report. The new report also highlights a relationship between obesity and the risk of 13 cancers. "Despite numerous studies on the health effects of overweight/obesity (excess body weight), the message has not been well disseminated. In particular, not many people are aware of the link of overweight/obesity to cancer risk," Hyuna Sung, one of the report's authors and a principal scientist at the American Cancer Society, wrote in an email.
Read full article.

Powered by OBR Oncology